ABOUT US

Protection against germs for up to 24 hours on skin and 30 days on surfaces

Zoono USA is seeking to change the conversation about how we deal with germs in this country by raising awareness of this innovative technology and by demonstrating product effectiveness across the broadest range of environments, from hospitals and facilities that treat humans to veterinary and animal settings to agriculture and manufacturing.

Zoono Group Limited (traded on the Australian Stock Exchange as ZNO) is a privately-owned company based in Auckland, New Zealand that specializes in the development, manufacture and global distribution of a suite of unique, proven, long-lasting and environmentally-friendly antimicrobial solutions.

Over the past 5 years, Zoono has developed many unique products (together with specific industry application protocols) that enable our customer’s partners and distributors to realize and maximize revenue-producing and commercial opportunities for these products and services.

Zoono Group has also developed (and owns) a wealth of intellectual property based around the “Zoono Molecule” – a unique, antimicrobial that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mold. Best of all, it has proven efficacy and longevity, it does not leach and cannot diminish in strength.

Today, Zoono Group has established a global network of customers and distributors that is spread across 42 countries and territories. As the market leader in its field, Zoono Group continues to develop new products and industry applications via a strong base of scientific, technical and training support.

Mission Statement

Zoono Group, through a strong foundation of research and development and the use of innovative technologies, is dedicated to providing a range of environmentally-friendly, trusted, high-quality, long-lasting and durable surface-acting antimicrobial products for commercial, industrial, health, consumer and residential use. Zoono Group is committed to building an industry leadership position in specific market segments where Zoono has a clear competitive advantage.

Meet our CEO

tom-image

Thomas French

CEO

Tom French has a long track record of bringing successful new technologies to market throughout the U.S. and internationally. His vision for Zoono USA is to develop a sustainable business across hospital and clinical settings, penetrating industrial sectors and making the product known and widely available in a broad range of manufacturing applications, introducing the technology to the veterinary market, the U.S. military and to the consumer via retail and the internet. The strategy is to seek best in class distribution partners with recognized expertise in each sector and build product to suit each market.

WordPress Video Lightbox Plugin